Treatment for taxane‐resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases

Abstract

AbstractCutaneous angiosarcoma (CAS) is a rare and highly aggressive type of vascular tumor. Although chemoradiotherapy with taxanes is recognized as a first‐line therapy for CAS, second‐line therapy for CAS remains controversial. From the above findings, the efficacy and safety profiles of taxane‐switch (change paclitaxel to docetaxel or vise), eribulin methylate, and pazopanib regimens in second‐line chemotherapy were evaluated retrospectively in 50 Japanese taxane‐resistant CAS patients. Although there was no significant difference in progression‐free survival (P = 0.3528) among the regimens, the incidence of all adverse events (AEs) (P = 0.0386), as well as severe G3 or more AEs (P = 0.0477) was significantly higher in the eribulin methylate group and pazopanib group than in the taxane‐switch group. The present data suggest that switching to another taxane should be considered for the treatment of taxane‐resistant CAS in second‐line therapy based on the safety profiles.